BIOMAT Database Logo BIOMAT Database Logo

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. 2016

D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai, China.

EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an invasive clinical procedure. Here, we dynamically monitored T790M mutation in circulating tumor DNA (ctDNA) using serial plasma samples from NSCLC patients receiving TKI through Droplet Digital PCR (ddPCR) method and the associations between overall survival (OS) starting from initial TKI treatment and the T790M ctDNA status detected in plasma were analyzed. Among 318 patients, 117 who acquired TKI resistance were eligible for the analysis. T790M ctDNA was detected in the plasma of 55/117 (47%) patients. Almost half of the T790M ctDNA positive patients were identified at a median time of 2.2 months prior to clinically progressive disease (PD). Furthermore, within the patients receiving TKI treatment at 2(nd) line or later, the T790M ctDNA positive group had significantly shorter OS than the negative group (median OS: 26.9 months versus NA, P = 0.0489). Our study demonstrates the feasibility of monitoring EGFR mutation dynamics in serial plasma samples from NSCLC patients receiving TKI therapy. T790M ctDNA can be detected in plasma before and after PD as a poor prognostic factor.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009360 Neoplastic Cells, Circulating Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors. Circulating Neoplastic Cells,Embolic Tumor Cells,Embolism, Tumor,Neoplasm Circulating Cells,Tumor Cells, Embolic,Cells, Neoplasm Circulating,Circulating Cells, Neoplasm,Circulating Tumor Cells,Cell, Circulating Neoplastic,Cell, Circulating Tumor,Cell, Embolic Tumor,Cell, Neoplasm Circulating,Cells, Circulating Neoplastic,Cells, Circulating Tumor,Cells, Embolic Tumor,Circulating Neoplastic Cell,Circulating Tumor Cell,Embolic Tumor Cell,Embolisms, Tumor,Neoplasm Circulating Cell,Neoplastic Cell, Circulating,Tumor Cell, Circulating,Tumor Cell, Embolic,Tumor Cells, Circulating,Tumor Embolism,Tumor Embolisms
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
January 2017, Cancer medicine,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
June 2014, Lung cancer (Amsterdam, Netherlands),
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.
January 2024, Therapeutic advances in medical oncology,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients.
October 2020, Experimental and molecular pathology,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
January 2020, Lung cancer (Amsterdam, Netherlands),
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
[Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy 
in Advanced NSCLC Patients with EGFR Mutations].
February 2019, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
March 2011, Journal of thoracic disease,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
October 2015, Annals of oncology : official journal of the European Society for Medical Oncology,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI.
January 2018, Oncology letters,
D Zheng, and X Ye, and M Z Zhang, and Y Sun, and J Y Wang, and J Ni, and H P Zhang, and L Zhang, and J Luo, and J Zhang, and L Tang, and B Su, and G Chen, and G Zhu, and Y Gu, and J F Xu
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
March 2023, BMC cancer,
Copied contents to your clipboard!